Zenotech Laboratories share price & results

Zenotech Laboratories Limited· Healthcare

Results to: Jun 2026
Ownership as of: Sept 2026

Hyderabad-based pharmaceutical manufacturer producing sterile formulations from a single Turkapally facility, operating as a Loan License manufacturer for Sun Pharmaceutical Industries.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

Metric	Value	Change	Basis	Period	Note
Revenue	10.6 ₹ crore	+10.2% YoY	Quarterly, as filed	Quarter to Jun 2026	Revenue from operations as filed.
Operating margin	8.1 %	−17.4 pts YoY	Operating profit / revenue	Quarter to Jun 2026	For the quarter; a change is in percentage points.
Net profit	-0.46 ₹ crore	−146.5% YoY	Quarterly, as filed	Quarter to Jun 2026	Profit after tax as filed.
Return on equity	Unavailable	+2.7 ptsFY Mar 2010 vs FY Mar 2009	Trailing twelve months	TTM · period unavailable	Not in the analysed materials. No older figure is substituted.
Free cash flow margin	Unavailable	+1.8 ptsFY Mar 2010 vs FY Mar 2008	Fiscal year	FY · period unavailable	Not in the analysed materials. No older figure is substituted.
Revenue growth (YoY)	Unavailable	+41.7 ptsFY Mar 2010 vs FY Mar 2009	Trailing twelve months	TTM · period unavailable	Not in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Price

₹38.4 −1.56% · −₹0.61

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −23.8% 1Y

1Y: ₹50.4 on 24 Oct 2025 → ₹38.4. High ₹53.49 (31 Oct 2025), low ₹34.29 (30 Mar 2026).

Previous close: ₹39.01
Market cap: ₹275 Cr
52-week range: ₹34.29 – ₹53.49
One year: −24.42%

Overview

Symbol: NSE:ZENOTECH
Sector: Healthcare
Exchange: NSE
Currency: INR

What Zenotech Laboratories Limited does

Based on the company's own presentations, annual report and earnings calls.

Zenotech Laboratories Limited is a pharmaceutical company based in Hyderabad, Telangana, engaged in the manufacture of sterile formulations. It operates from a single manufacturing facility, which also serves as its registered office, at Turkapally Village, Shamirpet Mandal. The company manufactures products offered by Sun Pharmaceutical Industries Limited, its holding company/promoter, under a Loan Licensing arrangement, and its current operations mainly depend on Sun Pharma.

Segments

Sterile formulations manufacturing

Manufacturing facilities: 1 (Turkapally Village, Shamirpet Mandal, Hyderabad, Telangana)
Permanent employees: 228 (FY25)
Manufacturing arrangement: Loan License manufacturer for Sun Pharmaceutical Industries Limited
Product focus: Sterile formulations

Founded 1989Headquarters Hyderabad, Telangana, IndiaEmployees 228 (FY25) Company website

Fundamentals

Ratios, each with its period

Current values with the period they cover; the trend reads across the 5 fiscal years held (Mar 2006 to Mar 2010).

Mar 2006 Mar 2007 Mar 2008 Mar 2009 Mar 2010
145.00 days 273.00 days 85.00 days 36.00 days 96.00 days

How it is calculated. Reported receivable days from the annual accounts.
Mar 2006 Mar 2007 Mar 2008 Mar 2009 Mar 2010
-167.00 days 149.00 days 240.00 days -18.00 days 123.00 days

How it is calculated. Reported debtor days plus inventory days less payable days.
Mar 2006 Mar 2007 Mar 2008 Mar 2009 Mar 2010
55.00 days 279.00 days 196.00 days 250.00 days 286.00 days

How it is calculated. Reported net working capital days from the annual accounts.
Mar 2006 Mar 2007 Mar 2008 Mar 2009 Mar 2010
0.00% 0.00% 0.00% 0.00% 0.00%

How it is calculated. Reported dividend payout as a percentage of annual profit.
Mar 2006 Mar 2007 Mar 2008 Mar 2009 Mar 2010
— — — — —

How it is calculated. Market capitalisation from the current stock record.

Mar 2006	Mar 2007	Mar 2008	Mar 2009	Mar 2010
145.00 days	273.00 days	85.00 days	36.00 days	96.00 days

Mar 2006	Mar 2007	Mar 2008	Mar 2009	Mar 2010
-167.00 days	149.00 days	240.00 days	-18.00 days	123.00 days

Mar 2006	Mar 2007	Mar 2008	Mar 2009	Mar 2010
55.00 days	279.00 days	196.00 days	250.00 days	286.00 days

Mar 2006	Mar 2007	Mar 2008	Mar 2009	Mar 2010
0.00%	0.00%	0.00%	0.00%	0.00%

Mar 2006	Mar 2007	Mar 2008	Mar 2009	Mar 2010
—	—	—	—	—

A dash means inputs are missing or too old, the ratio does not apply, or the value is outside the supported range. FY uses the reported fiscal period; TTM the latest twelve months; valuations use the current market cap with the chosen earnings period. Screen Indian stocks on these ratios →

Financials

What the filings say

Net profit, year on year: −146% (quarter to jun 2026 against jun 2025).

In ₹ crore. Oldest period first.

Line item	Sept 2024	Dec 2024	Mar 2025	Jun 2025	Sept 2025	Dec 2025	Mar 2026	Jun 2026
Sales	10	11	12	10	11	13	10	11
Expenses	7	7	8	7	9	9	10	10
Operating profit	2	4	4	2	2	4	0	1
Operating margin	24.7%	34.4%	36.9%	25.5%	20.4%	33.2%	1.7%	8.1%
Other income	2	1	0	1	1	0	1	0
Interest	0	0	0	0	0	0	0	0
Depreciation	2	2	2	2	2	2	2	2
Profit before tax	2	3	3	1	1	3	-1	-1
Tax rate	42.5%	45.7%	61.3%	22.7%	165.9%	25.5%	235.1%	−25.0%
Net profit	1	2	1	1	-1	2	-3	-0
EPS (₹ per share)	0.22	0.28	0.20	0.16	-0.14	0.32	-0.52	-0.08

Source: Inve data · income statement, quarterly · to Jun 2026

In ₹ crore. Oldest period first.

Line item	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Sales	42	41	43	44
Expenses	22	24	29	34
Operating profit	21	17	14	9
Other income	1	1	3	2
Interest	0	0	0	0
Depreciation	7	7	7	7
Profit before tax	15	11	11	4
Net profit	12	8	6	-1

Source: Inve data · income statement, annual · to Mar 2026

In ₹ crore. Oldest period first.

Line item	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Sept 2025	Mar 2026
Equity capital	61	61	61	61	61	61
Reserves	10	21	30	35	35	34
Borrowings	6	0	0	0	0	0
Other liabilities	17	19	16	15	15	16
Total liabilities	94	101	106	111	111	111
Fixed assets	71	65	66	61	60	62
Capital work in progress	0	5	2	4	5	4
Investments	0	0	0	0	0	0
Other assets	23	31	39	46	46	45
Total assets	94	101	106	111	111	111

Source: Inve data · balance sheet · to Mar 2026

In ₹ crore. Oldest period first.

Line item	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operations	6	18	21	12	10	10
Cash from investing	-5	-2	-6	-21	15	-6
Cash from financing	0	-16	-6	0	0	0
Net cash flow	1	-0	9	-9	25	4
Free cash flow	1	16	14	8	6	2

Source: Inve data · cash flow · to Mar 2026

In days and %. Oldest period first.

Line item	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	62	39	29	29	63	73
Cash conversion cycle	62	39	29	29	63	73
Working capital days	-164	-106	-99	-63	-28	-12
Return on capital employed	0.5%	15.3%	18.4%	12.9%	9.4%	4.6%
Dividend payout	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%

Source: Inve data · annual ratios · to Mar 2026

Ownership

Who owns it

Promoters hold 68.84% as of Sept 2026; institutions added 0.00 pts since Jun 2026.

Promoters 0.00 pts 68.84%
Domestic institutions 0.00 pts 0.01%
Government 0.00 pts 0.98%
Public 0.00 pts 30.17%

9,959 shareholders on the register.

Source: Exchange shareholding filings · to Sept 2026 · 8 filings held

Who was buying across the market this quarter

Who is on the register

Named in the Sep 2026 filing

Every holder of Zenotech Laboratories Limited above SEBI's 1% disclosure line, and what changed since Jun 2026.

Holder	Stake	Change
	68.84%	unchanged
	5.52%	unchanged
	3.98%	unchanged
	3.33%	unchanged
	1.72%	unchanged
	1.14%	unchanged

A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.

Your own record

Start an Inve Case for Zenotech Laboratories Limited

Free account: one company. Everything above stays public.

Write why you follow Zenotech Laboratories Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Zenotech Laboratories Limited

Guides on how to read this kind of business and the numbers that matter.